PL2970267T6 - Modulatory P2X7 - Google Patents

Modulatory P2X7

Info

Publication number
PL2970267T6
PL2970267T6 PL14718857T PL14718857T PL2970267T6 PL 2970267 T6 PL2970267 T6 PL 2970267T6 PL 14718857 T PL14718857 T PL 14718857T PL 14718857 T PL14718857 T PL 14718857T PL 2970267 T6 PL2970267 T6 PL 2970267T6
Authority
PL
Poland
Prior art keywords
modulators
Prior art date
Application number
PL14718857T
Other languages
English (en)
Other versions
PL2970267T3 (pl
Inventor
Manuel Jesus Alcazar Vaca
Brett D. Allison
Jose Ignacio Andres Gil
Christa C. Chrovian
Heather R. COATE
Meri De Angelis
Xiaohu Deng
Curt A. Dvorak
Christine F. GELIN
Michael A. Letavic
Jimmy T. Liang
Neelakandha S. Mani
Jason C. Rech
Brad M. Savall
Akinola Soyode-Johnson
Brice M. STENNE
Devin M. Swanson
Jessica L. WALL
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL2970267T3 publication Critical patent/PL2970267T3/pl
Publication of PL2970267T6 publication Critical patent/PL2970267T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
PL14718857T 2013-03-14 2014-03-14 Modulatory P2X7 PL2970267T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786260P 2013-03-14 2013-03-14
EP14718857.7A EP2970267B3 (en) 2013-03-14 2014-03-14 P2x7 modulators
PCT/US2014/027522 WO2014152604A1 (en) 2013-03-14 2014-03-14 P2x7 modulators

Publications (2)

Publication Number Publication Date
PL2970267T3 PL2970267T3 (pl) 2017-11-30
PL2970267T6 true PL2970267T6 (pl) 2018-11-30

Family

ID=50543353

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14718857T PL2970267T6 (pl) 2013-03-14 2014-03-14 Modulatory P2X7

Country Status (33)

Country Link
US (8) US9066946B2 (pl)
EP (3) EP3495365A1 (pl)
JP (1) JP6293861B2 (pl)
KR (5) KR102319857B1 (pl)
CN (2) CN110003200B (pl)
AR (2) AR095530A1 (pl)
AU (5) AU2014239291B2 (pl)
BR (1) BR112015023142B1 (pl)
CA (1) CA2906085C (pl)
CL (3) CL2015002655A1 (pl)
CY (1) CY1119110T1 (pl)
DK (2) DK2970267T6 (pl)
EA (1) EA028816B1 (pl)
ES (2) ES2635318T7 (pl)
HR (1) HRP20171168T4 (pl)
HU (1) HUE032877T2 (pl)
IL (1) IL240880B (pl)
JO (1) JO3773B1 (pl)
LT (1) LT2970267T (pl)
ME (1) ME02802B (pl)
MX (2) MX364796B (pl)
PH (1) PH12015501930A1 (pl)
PL (1) PL2970267T6 (pl)
PT (2) PT3239151T (pl)
RS (1) RS56315B2 (pl)
SG (2) SG11201507259UA (pl)
SI (1) SI2970267T1 (pl)
SM (1) SMT201700352T1 (pl)
TW (2) TWI599567B (pl)
UA (1) UA116467C2 (pl)
UY (3) UY35469A (pl)
WO (1) WO2014152604A1 (pl)
ZA (1) ZA201507627B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI599567B (zh) * 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015172196A1 (en) * 2014-05-13 2015-11-19 Monash University Heterocyclic compounds and use of same
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 6員複素環誘導体およびそれらを含有する医薬組成物
CA2994027C (en) * 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
EP3527568A4 (en) 2016-10-17 2020-03-18 Shionogi & Co., Ltd BICYCLIC NITROGENATED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREFOR
EP3548613B1 (en) 2016-12-02 2021-01-27 Fraunhofer Gesellschaft zur Förderung der Angewand Bacterial glutaminyl cyclase inhibitors and use thereof in the treatment of periodontitis
AU2018235561B2 (en) * 2017-03-13 2020-06-18 Asahi Kasei Pharma Corporation Tetrahydroquinoline derivatives as P2X7 receptor antagonists
WO2019099509A1 (en) * 2017-11-14 2019-05-23 Second Genome, Inc. Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
MD3746429T2 (ro) * 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
JP7413368B2 (ja) * 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ.ベー. モノアシルグリセロールリパーゼ調節因子
MA53721A (fr) * 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN109400605A (zh) * 2018-11-27 2019-03-01 复旦大学附属中山医院 一种p2x7受体显像剂及其制备方法
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
WO2021145655A1 (ko) 2020-01-13 2021-07-22 압타바이오 주식회사 신규한 피라졸 유도체
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CN115894452B (zh) * 2021-08-18 2024-04-09 四川大学 一种p2x7受体抑制剂
EP4793276A1 (en) 2023-10-30 2026-08-19 Fudan University Drug for diagnosing diabetic nephropathy and use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US20060100233A1 (en) * 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
FR2857363B1 (fr) * 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DE602005022320D1 (de) 2004-08-23 2010-08-26 Merck Sharp & Dohme Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
US8349858B2 (en) 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
EP2185560A4 (en) * 2007-08-10 2011-10-05 Lundbeck & Co As H HETEROARYLAMIDE ANALOGS
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
JP5369173B2 (ja) 2008-04-22 2013-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン若しくはイソキノリン置換p2x7アンタゴニスト
US8309578B2 (en) * 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2010125102A1 (en) 2009-04-29 2010-11-04 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
EP2491031B1 (en) 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
CA2793313C (en) 2010-04-02 2018-01-23 Euroscreen Sa Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US20110252717A1 (en) 2010-04-16 2011-10-20 Graf Fernandez Rodrigo Foldable structures for a construction
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
JP5205547B1 (ja) 2012-04-20 2013-06-05 株式会社ノイズ研究所 放射信号可視化装置
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
BR112015008480A2 (pt) 2012-10-15 2017-07-04 Epizyme Inc compostos de benzeno substituído
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CN105188371A (zh) 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
CN105189461B (zh) 2013-03-14 2018-05-15 葛兰素史克知识产权第二有限公司 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
CA2902174A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6603649B2 (ja) 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
ES2721018T3 (es) 2013-03-29 2019-07-26 Ogeda S A N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands

Also Published As

Publication number Publication date
IL240880A0 (en) 2015-10-29
MX2015012095A (es) 2016-05-10
US9464084B2 (en) 2016-10-11
CL2017002609A1 (es) 2018-03-16
SI2970267T1 (sl) 2017-08-31
DK2970267T3 (en) 2017-07-24
WO2014152604A1 (en) 2014-09-25
KR20150127723A (ko) 2015-11-17
KR20210132743A (ko) 2021-11-04
AU2019203186B2 (en) 2021-06-24
PT3239151T (pt) 2019-01-28
CN110003200B (zh) 2021-11-26
KR102319857B1 (ko) 2021-11-01
AU2021236451A1 (en) 2021-10-14
UY39887A (es) 2023-06-15
DK3239151T3 (en) 2019-01-21
TWI599567B (zh) 2017-09-21
US11225478B2 (en) 2022-01-18
CL2015002655A1 (es) 2016-03-04
IL240880B (en) 2019-05-30
AU2014239291B2 (en) 2017-06-15
EA028816B1 (ru) 2018-01-31
US10112937B2 (en) 2018-10-30
US9066946B2 (en) 2015-06-30
CN105209464B (zh) 2019-01-01
EP3495365A1 (en) 2019-06-12
ZA201507627B (en) 2023-11-29
CN105209464A (zh) 2015-12-30
CA2906085A1 (en) 2014-09-25
RS56315B1 (sr) 2017-12-29
CN110003200A (zh) 2019-07-12
KR102516711B1 (ko) 2023-03-30
SG11201507259UA (en) 2015-10-29
CA2906085C (en) 2023-01-03
ES2635318T3 (es) 2017-10-03
US20160376271A1 (en) 2016-12-29
ES2704024T3 (es) 2019-03-13
US20240116930A1 (en) 2024-04-11
MX2022011795A (es) 2022-10-10
ME02802B (me) 2018-01-20
US20150322062A1 (en) 2015-11-12
MX364796B (es) 2019-05-07
PH12015501930A1 (en) 2016-01-04
US11820770B2 (en) 2023-11-21
AU2024201709B2 (en) 2026-06-04
EP2970267B1 (en) 2017-05-24
BR112015023142A8 (pt) 2019-12-03
AR123048A2 (es) 2022-10-26
AR095530A1 (es) 2015-10-21
DK2970267T6 (en) 2018-09-03
ES2635318T7 (es) 2018-09-11
AU2019203186A1 (en) 2019-05-30
KR20250004140A (ko) 2025-01-07
SG10201700889PA (en) 2017-03-30
US10703749B2 (en) 2020-07-07
US20160039809A1 (en) 2016-02-11
AU2014239291A1 (en) 2015-09-17
PL2970267T3 (pl) 2017-11-30
TW201446762A (zh) 2014-12-16
RS56315B2 (sr) 2018-08-31
SMT201700352T1 (it) 2017-09-07
UY35469A (es) 2014-09-30
EP3239151A1 (en) 2017-11-01
UY39888A (es) 2022-09-30
KR20220044376A (ko) 2022-04-07
KR20230049754A (ko) 2023-04-13
AU2024201709A1 (en) 2024-04-04
BR112015023142B1 (pt) 2023-05-02
HRP20171168T1 (hr) 2017-10-06
TW201740940A (zh) 2017-12-01
JP6293861B2 (ja) 2018-03-14
TWI644671B (zh) 2018-12-21
EP2970267B3 (en) 2018-05-30
LT2970267T (lt) 2017-07-10
US20200325138A1 (en) 2020-10-15
JO3773B1 (ar) 2021-01-31
JP2016515135A (ja) 2016-05-26
AU2017206153A1 (en) 2017-08-17
US20140275015A1 (en) 2014-09-18
US12247027B2 (en) 2025-03-11
HK1218541A1 (en) 2017-02-24
US20220213095A1 (en) 2022-07-07
PT2970267T (pt) 2017-08-25
KR102500076B1 (ko) 2023-02-14
HUE032877T2 (hu) 2017-11-28
UA116467C2 (uk) 2018-03-26
US20190092770A1 (en) 2019-03-28
EA201591748A1 (ru) 2016-02-29
CY1119110T1 (el) 2018-02-14
EP2970267A1 (en) 2016-01-20
BR112015023142A2 (pt) 2017-07-18
CL2017002610A1 (es) 2018-03-16
US10150765B2 (en) 2018-12-11
AU2021236451B2 (en) 2024-02-01
EP3239151B1 (en) 2018-11-07
AU2017206153B2 (en) 2019-02-14
NZ711699A (en) 2020-10-30
HRP20171168T4 (hr) 2018-09-21

Similar Documents

Publication Publication Date Title
ES2635318T7 (es) Moduladores P2X7
DK3036329T3 (da) Immunonkolytiske terapier
DK3004155T3 (da) Peptidforbindelse
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK2956698T3 (da) Bindestrimler
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
EP2972725A4 (en) SURVIVOR FACES
EP3525454C0 (en) DISPLAY DEVICE
EP2982408A4 (en) INTERCONNECTS
EP2943489A4 (en) DEUTERATED MOMELOTINIB
DK2946640T3 (da) Langmuir-probe
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
ES1078715Y (es) Mosquitera
ES1088356Y (es) Libro electronico